English
Insider transactions
EDGARMapLight Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 10 transactions, 5,663,969 shares
- Sum of shares × price per share: 66,229,342.1075
- Open-market sales (code S)
- 145 transactions, 1,118,271 shares
- Sum of shares × price per share: 30,239,360.15
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 203
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 Filed 2026-10-16 | GILLIS JONATHAN Officer: CAO and Interim CFO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10,167 | 8.08 | 82,149.36Derived: shares × price per share. Exact value 82149.36. | 142,315 | Direct (D) | No | F1, F2
| Open filing 0001709954-26-000014 Read from the filing’s XML Dispute this row |
| 2026-10-15 Filed 2026-10-16 | Kroeger Christopher A. Director · Officer: Chief Executive Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 73,691 | 8.08 | 595,423.28Derived: shares × price per share. Exact value 595423.28. | 1,195,909 | Direct (D) | No | F1, F2
| Open filing 0001658918-26-000018 Read from the filing’s XML Dispute this row |
| 2026-10-15 Filed 2026-10-16 | Foff Erin Pennock Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 15,355 | 8.08 | 124,068.4Derived: shares × price per share. Exact value 124068.40. | 296,906 | Direct (D) | No | F1, F2
| Open filing 0002021233-26-000016 Read from the filing’s XML Dispute this row |
| 2026-10-15 Filed 2026-10-16 | Hanson Kristopher Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 9,020 | 8.08 | 72,881.6Derived: shares × price per share. Exact value 72881.60. | 128,024 | Direct (D) | No | F1, F2
| Open filing 0001789970-26-000018 Read from the filing’s XML Dispute this row |
| 2026-10-15 Filed 2026-10-16 | Kreitzer Anatol Officer: Chief Discovery Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 12,248 | 7.84 | 96,024.32Derived: shares × price per share. Exact value 96024.32. | 168,678 | Direct (D) | No | F1
| Open filing 0002021238-26-000014 Read from the filing’s XML Dispute this row |
| 2026-10-15 Filed 2026-10-16 | Lillie James Woodruff Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 11,513 | 8.08 | 93,025.04Derived: shares × price per share. Exact value 93025.04. | 198,597 | Direct (D) | No | F1, F2
| Open filing 0001728746-26-000018 Read from the filing’s XML Dispute this row |
| 2026-09-16 Filed 2026-09-18 | Hanson Kristopher Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,509 | 11.67 | 192,660.03Derived: shares × price per share. Exact value 192660.03. | 137,044 | Direct (D) | Yes | F1, F2
| Open filing 0001789970-26-000016 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Kroeger Christopher A. Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 23,145 | 0 | — | 1,269,600 | Direct (D) | No | F1, F2
| Open filing 0001658918-26-000016 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Kroeger Christopher A. Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 93,955 | 0 | — | 93,955 | Direct (D) | No | F4
| Open filing 0001658918-26-000016 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | GILLIS JONATHAN Officer: CAO and Interim CFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,020 | 0 | — | 150,260 | Direct (D) | No | F1, F2
| Open filing 0001709954-26-000012 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | GILLIS JONATHAN Officer: CAO and Interim CFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,222 | 0 | — | 152,482 | Direct (D) | No | F3, F2
| Open filing 0001709954-26-000012 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | GILLIS JONATHAN Officer: CAO and Interim CFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 24,455 | 0 | — | 24,455 | Direct (D) | No | F4
| Open filing 0001709954-26-000012 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | GILLIS JONATHAN Officer: CAO and Interim CFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,813 | 0 | — | 2,813 | Direct (D) | No | F5
| Open filing 0001709954-26-000012 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Kreitzer Anatol Officer: Chief Discovery Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,020 | 0 | — | 180,926 | Direct (D) | No | F1, F2
| Open filing 0002021238-26-000012 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Kreitzer Anatol Officer: Chief Discovery Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 24,455 | 0 | — | 24,455 | Direct (D) | No | F3
| Open filing 0002021238-26-000012 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Lillie James Woodruff Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 7,730 | 0 | — | 210,110 | Direct (D) | No | F1, F2
| Open filing 0001728746-26-000016 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Lillie James Woodruff Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 31,395 | 0 | — | 31,395 | Direct (D) | No | F3
| Open filing 0001728746-26-000016 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Foff Erin Pennock Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 13,360 | 0 | — | 312,261 | Direct (D) | No | F1, F2
| Open filing 0002021233-26-000014 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Foff Erin Pennock Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,240 | 0 | — | 54,240 | Direct (D) | No | F3
| Open filing 0002021233-26-000014 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Hanson Kristopher Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 7,730 | 0 | — | 153,553 | Direct (D) | No | F1, F2
| Open filing 0001789970-26-000014 Read from the filing’s XML Dispute this row |
| 2026-08-17 Filed 2026-08-19 | Hanson Kristopher Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 31,395 | 0 | — | 31,395 | Direct (D) | No | F3
| Open filing 0001789970-26-000014 Read from the filing’s XML Dispute this row |
| 2026-08-14 Filed 2026-08-18 | Catalyst4, Inc. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 4,400,000 | 11.38 | 50,072,000Derived: shares × price per share. Exact value 50072000.00. | 25,306,689 | Indirect (I) See footnote | No | F1
| Open filing 0001900201-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-14 Filed 2026-08-18 | Catalyst4, Inc. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,928,686 | 11.3799 | 33,328,153.8114Derived: shares × price per share. Exact value 33328153.8114. | 2,928,686 | Indirect (I) See footnote | No | F2, F3, F1
| Open filing 0001900201-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-03 Filed 2026-08-04 | Lillie James Woodruff Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 22,082 | 12.54 | 276,908.28Derived: shares × price per share. Exact value 276908.28. | 202,380 | Direct (D) | Yes | F1, F2
| Open filing 0001728746-26-000014 Read from the filing’s XML Dispute this row |
| 2026-07-30 Filed 2026-07-30 | Catalyst4, Inc. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,000,000 | 13 | 13,000,000Derived: shares × price per share. Exact value 13000000. | 20,906,689 | Indirect (I) See footnote | No | F2
| Open filing 0001900201-26-000003 Read from the filing’s XML Dispute this row |
| 2026-07-29 Filed 2026-07-30 | Catalyst4, Inc. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 3,000 | 12.63 | 37,890Derived: shares × price per share. Exact value 37890.00. | 19,906,689 | Indirect (I) See footnote | No | F2
| Open filing 0001900201-26-000003 Read from the filing’s XML Dispute this row |
| 2026-07-28 Filed 2026-07-30 | Catalyst4, Inc. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 141,088 | 10.7416 | 1,515,510.8608Derived: shares × price per share. Exact value 1515510.8608. | 19,838,552 | Indirect (I) See footnote | No | F1, F2
| Open filing 0001900201-26-000003 Read from the filing’s XML Dispute this row |
| 2026-07-28 Filed 2026-07-30 | Catalyst4, Inc. 10% owner | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 65,137 | 11.6891 | 761,392.9067Derived: shares × price per share. Exact value 761392.9067. | 19,903,689 | Indirect (I) See footnote | No | F3, F2
| Open filing 0001900201-26-000003 Read from the filing’s XML Dispute this row |
| 2026-07-28 Filed 2026-07-28 | Cox Troy Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 15,620 | 9.52 | 148,702.4Derived: shares × price per share. Exact value 148702.40. | 15,620 | Indirect (I) By trust | No | F1, F2
| Open filing 0001696923-26-000007 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | GILLIS JONATHAN Officer: CAO and Interim CFO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 600 | 36.51 | 21,906Derived: shares × price per share. Exact value 21906.00. | 162,109 | Direct (D) | Yes | F6, F7
| Open filing 0001709954-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | GILLIS JONATHAN Officer: CAO and Interim CFO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,969 | 37.61 | 638,204.09Derived: shares × price per share. Exact value 638204.09. | 145,140 | Direct (D) | Yes | F6, F8
| Open filing 0001709954-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | GILLIS JONATHAN Officer: CAO and Interim CFO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 900 | 38.17 | 34,353Derived: shares × price per share. Exact value 34353.00. | 144,240 | Direct (D) | Yes | F6, F9
| Open filing 0001709954-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | Kreitzer Anatol Officer: Chief Discovery Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,833 | 37.05 | 104,962.65Derived: shares × price per share. Exact value 104962.65. | 189,246 | Direct (D) | Yes | F6, F7
| Open filing 0002021238-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | Kreitzer Anatol Officer: Chief Discovery Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 14,140 | 37.70 | 533,078Derived: shares × price per share. Exact value 533078.00. | 175,106 | Direct (D) | Yes | F6, F8
| Open filing 0002021238-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-20 | Kreitzer Anatol Officer: Chief Discovery Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 200 | 38.39 | 7,678Derived: shares × price per share. Exact value 7678.00. | 174,906 | Direct (D) | Yes | F6
| Open filing 0002021238-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-17 | Lillie James Woodruff Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 2,077 | 37.90 | 78,718.3Derived: shares × price per share. Exact value 78718.30. | 224,462 | Direct (D) | No | F1, F6
| Open filing 0001728746-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-17 | Foff Erin Pennock Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,656 | 37.90 | 138,562.4Derived: shares × price per share. Exact value 138562.40. | 298,901 | Direct (D) | Yes | F4, F9
| Open filing 0002021233-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-17 | Hanson Kristopher Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,130 | 37.90 | 42,827Derived: shares × price per share. Exact value 42827.00. | 145,823 | Direct (D) | No | F1, F6
| Open filing 0001789970-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-17 Filed 2026-07-17 | Kroeger Christopher A. Director · Officer: Chief Executive Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,779 | 37.90 | 635,924.1Derived: shares × price per share. Exact value 635924.10. | 1,246,455 | Direct (D) | No | F1, F6
| Open filing 0001658918-26-000014 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-20 | GILLIS JONATHAN Officer: CAO and Interim CFO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 6,979 | 36.66 | 255,850.14Derived: shares × price per share. Exact value 255850.14. | 164,185 | Direct (D) | Yes | F1, F4
| Open filing 0001709954-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-20 | GILLIS JONATHAN Officer: CAO and Interim CFO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,476 | 37.44 | 55,261.44Derived: shares × price per share. Exact value 55261.44. | 162,709 | Direct (D) | Yes | F1, F5
| Open filing 0001709954-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-20 | Kreitzer Anatol Officer: Chief Discovery Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 7,464 | 36.66 | 273,630.24Derived: shares × price per share. Exact value 273630.24. | 193,671 | Direct (D) | Yes | F1, F4
| Open filing 0002021238-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-20 | Kreitzer Anatol Officer: Chief Discovery Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,592 | 37.44 | 59,604.48Derived: shares × price per share. Exact value 59604.48. | 192,079 | Direct (D) | Yes | F1, F5
| Open filing 0002021238-26-000010 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Lillie James Woodruff Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 5,009 | 36.45 | 182,578.05Derived: shares × price per share. Exact value 182578.05. | 230,077 | Direct (D) | No | F1, F4
| Open filing 0001728746-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Lillie James Woodruff Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 3,526 | 37.26 | 131,378.76Derived: shares × price per share. Exact value 131378.76. | 226,551 | Direct (D) | No | F1, F5
| Open filing 0001728746-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Lillie James Woodruff Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 12 | 37.96 | 455.52Derived: shares × price per share. Exact value 455.52. | 226,539 | Direct (D) | No | F1
| Open filing 0001728746-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Foff Erin Pennock Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 9,163 | 36.46 | 334,082.98Derived: shares × price per share. Exact value 334082.98. | 308,441 | Direct (D) | Yes | F4, F7
| Open filing 0002021233-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Foff Erin Pennock Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 5,865 | 37.26 | 218,529.9Derived: shares × price per share. Exact value 218529.90. | 302,576 | Direct (D) | Yes | F4, F8
| Open filing 0002021233-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Foff Erin Pennock Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 19 | 37.96 | 721.24Derived: shares × price per share. Exact value 721.24. | 302,557 | Direct (D) | Yes | F4
| Open filing 0002021233-26-000012 Read from the filing’s XML Dispute this row |
| 2026-07-16 Filed 2026-07-17 | Hanson Kristopher Officer: General Counsel | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,776 | 36.45 | 174,085.2Derived: shares × price per share. Exact value 174085.20. | 150,295 | Direct (D) | No | F1, F4
| Open filing 0001789970-26-000012 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–50 of 105
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| FCPM III SERVICES B.V. Partly reported under another manager | 4,428,328 SH | 45,124,662 dollars | Higher by 1,201,928 Prior quarter: 3,226,400 | Open filing 0001193125-26-462149 Filed 2026-11-16 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 3,599,556 SH | 36,679,475 dollars | Higher by 1,651,244 Prior quarter: 1,948,312 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| Nan Fung Group Holdings Ltd Partly reported under another manager | 2,300,328 SH | 23,440,342 dollars | Higher by 1,329,075 Prior quarter: 971,253 | Open filing 0001012975-26-001047 Filed 2026-11-13 Dispute this row |
| NOVO HOLDINGS A/S | 2,086,622 SH | 21,262,678 dollars | Lower by 1,600,000 Prior quarter: 3,686,622 | Open filing 0001388325-26-000051 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 1,712,729 SH | 17,452,709 dollars | Higher by 687,595 Prior quarter: 1,025,134 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| FMR LLC Partly reported under another manager | 1,541,940 SH | 15,712,368 dollars | Higher by 718,384 Prior quarter: 823,556 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| Deep Track Capital, LP | 1,318,101 SH | 13,431,449 dollars | Not in the prior quarter’s filings read | Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row |
| BAKER BROS. ADVISORS LP | 1,166,763 SH | 11,889,315 dollars | Higher by 802,058 Prior quarter: 364,705 | Open filing 0001104659-26-128308 Filed 2026-11-16 Dispute this row |
| PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager | 1,132,288 SH | 11,539 dollars | Lower by 290,647 Prior quarter: 1,422,935 | Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row |
| T. Rowe Price Investment Management, Inc. | 945,216 SH | 9,632 dollars | Lower by 1,836,512 Prior quarter: 2,781,728 | Open filing 0001897612-26-000766 Filed 2026-11-16 Dispute this row |
| Sanofi | 912,041 SH | 9,293,698 dollars | Unchanged Prior quarter: 912,041 | Open filing 0001193125-26-448717 Filed 2026-11-05 Dispute this row |
| 5AM Venture Management, LLC | 741,893 SH | 7,559,890 dollars | Lower by 208,118 Prior quarter: 950,011 | Open filing 0001799883-26-000004 Filed 2026-11-16 Dispute this row |
| ADAR1 Capital Management, LLC | 725,165 SH | 7,389,431 dollars | Higher by 698,668 Prior quarter: 26,497 | Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row |
| Velan Capital Investment Management LP | 624,703 SH | 6,365,724 dollars | Higher by 131,810 Prior quarter: 492,893 | Open filing 0001848809-26-000006 Filed 2026-11-16 Dispute this row |
| MARSHALL WACE, LLP Partly reported under another manager | 612,310 SH | 6,239,438 dollars | Higher by 606,510 Prior quarter: 5,800 | Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row |
| Pivotal bioVenture Partners Investment Advisor LLC Partly reported under another manager | 611,446 SH | 6,230,635 dollars | Unchanged Prior quarter: 611,446 | Open filing 0001012975-26-001045 Filed 2026-11-13 Dispute this row |
| Blue Owl Capital Holdings LP Partly reported under another manager | 556,371 SH | 5,669,420 dollars | Lower by 173,558 Prior quarter: 729,929 | Open filing 0001193125-26-459653 Filed 2026-11-13 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 516,022 SH | 5,258,264 dollars | Higher by 507,024 Prior quarter: 8,998 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 440,731 SH | 4,492,445 dollars | Higher by 38,680 Prior quarter: 402,051 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Point72 Asset Management, L.P. | 426,261 SH | 4,343,600 dollars | Not in the prior quarter’s filings read | Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 423,678 SH | 4,317,279 dollars | Higher by 294,837 Prior quarter: 128,841 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| Capital World Investors Partly reported under another manager | 415,760 SH | 4,236,594 dollars | Higher by 30 Prior quarter: 415,730 | Open filing 0001422849-26-000169 Filed 2026-11-12 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 396,076 SH | 4,036,014 dollars | Lower by 388,074 Prior quarter: 784,150 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| Trexquant Investment LP Partly reported under another manager | 363,736 SH | 3,706,470 dollars | Higher by 299,944 Prior quarter: 63,792 | Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 313,586 SH | 3,195,441 dollars | Lower by 538,564 Prior quarter: 852,150 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| LAZARD ASSET MANAGEMENT LLC | 263,905 SH | 2,689,192 dollars | Higher by 183,823 Prior quarter: 80,082 | Open filing 0001207017-26-000051 Filed 2026-11-16 Dispute this row |
| BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager | 245,219 SH | 2,498,782 dollars | Higher by 174,735 Prior quarter: 70,484 | Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. Partly reported under another manager | 170,862 SH | 1,741,084 dollars | Unchanged Prior quarter: 170,862 | Open filing 0001520354-26-000046 Filed 2026-11-13 Dispute this row |
| DAFNA Capital Management LLC | 155,579 SH | 1,585,350 dollars | Lower by 15,427 Prior quarter: 171,006 | Open filing 0001389933-26-000010 Filed 2026-11-16 Dispute this row |
| TD ASSET MANAGEMENT INC | 140,888 SH | 1,430,013 dollars | Higher by 86,362 Prior quarter: 54,526 | Open filing 0001193125-26-460060 Filed 2026-11-13 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 129,095 SH | 1,315,478 dollars | Higher by 12,443 Prior quarter: 116,652 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 122,473 SH | 1,248,000 dollars | Lower by 14,345 Prior quarter: 136,818 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 120,871 SH | 1,231,675 dollars | Higher by 24,110 Prior quarter: 96,761 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| SUPERSTRING CAPITAL MANAGEMENT LP | 118,304 SH | 1,205,518 dollars | Lower by 7,128 Prior quarter: 125,432 | Open filing 0001931118-26-000011 Filed 2026-11-16 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 116,464 SH | 1,186,768 dollars | Lower by 6,671 Prior quarter: 123,135 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| UBS Group AG Partly reported under another manager | 102,232 SH | 1,041,744 dollars | Lower by 19,796 Prior quarter: 122,028 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| BARCLAYS PLC Partly reported under another manager | 85,813 SH | 874,434 dollars | Higher by 72,838 Prior quarter: 12,975 | Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 85,475 SH | 870,990 dollars | Higher by 59,724 Prior quarter: 25,751 | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| HRT FINANCIAL LP | 83,737 SH | 853 dollars | Higher by 31,754 Prior quarter: 51,983 | Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE Partly reported under another manager | 83,274 SH | 848,562 dollars | Higher by 76,234 Prior quarter: 7,040 | Open filing 0001145443-26-000111 Filed 2026-11-13 Dispute this row |
| Quadrature Capital Ltd Partly reported under another manager | 74,485 SH | 759,002 dollars | Not in the prior quarter’s filings read | Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row |
| XTX Topco Ltd Partly reported under another manager | 63,396 SH | 646,005 dollars | Higher by 38,477 Prior quarter: 24,919 | Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 60,716 SH | 618,697 dollars | Higher by 22,412 Prior quarter: 38,304 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| CITIGROUP INC Partly reported under another manager | 59,173 SH | 602,973 dollars | Higher by 42,122 Prior quarter: 17,051 | Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row |
| Jump Financial, LLC Partly reported under another manager | 58,461 SH | 595,718 dollars | Higher by 33,239 Prior quarter: 25,222 | Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row |
| Schonfeld Strategic Advisors LLC | 54,016 SH | 550,422 dollars | Not in the prior quarter’s filings read | Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row |
| JANE STREET GROUP, LLC Option: Call Partly reported under another manager | 34,800 SH | 354,612 dollars | Not in the prior quarter’s filings read | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| Nuveen, LLC Partly reported under another manager | 30,957 SH | 315,451 dollars | Higher by 13,036 Prior quarter: 17,921 | Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row |
| Bank of New York Mellon Corp Partly reported under another manager | 30,218 SH | 307,922 dollars | Lower by 192 Prior quarter: 30,410 | Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row |
| D. E. Shaw Co., Inc. Partly reported under another manager | 29,369 SH | 299,270 dollars | Not in the prior quarter’s filings read | Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Paradigm Biocapital Advisors LP 685,852 SH
- Siren, L.L.C. 450,000 SH
- Freestone Grove Partners LP 168,912 SH
- Sixth Street Partners Management Company, L.P. 136,818 SH
- STEMPOINT CAPITAL LP 106,906 SH
- SEVEN GRAND MANAGERS, LLC 100,000 SH
- Boxer Capital Management, LLC 75,000 SH
- Burkehill Global Management, LP 75,000 SH
- WELLINGTON MANAGEMENT GROUP LLP 51,917 SH
- Jain Global LLC 45,551 SH
- BRIDGEWAY CAPITAL MANAGEMENT, LLC 35,000 SH
- Weiss Asset Management LP 33,094 SH
- Rafferty Asset Management, LLC 13,853 SH
- Quantinno Capital Management LP 11,339 SH
- Jupiter Research Capital (Asia) Ltd 8,018 SH
- AMERICAN CENTURY COMPANIES INC 7,470 SH
- MetLife Investment Management, LLC 7,353 SH
- PROFUND ADVISORS LLC 6,956 SH
- RENAISSANCE TECHNOLOGIES LLC 6,937 SH
- RAYMOND JAMES FINANCIAL INC 6,455 SH
- Invesco Ltd. 5,729 SH
- Aster Capital Management (DIFC) Ltd 1,480 SH
- Pinnacle Wealth Planning Services, Inc. 1,265 SH
- Penserra Capital Management LLC 1,088 SH
- MERCER GLOBAL ADVISORS INC /ADV 590 SH
- NISA INVESTMENT ADVISORS, LLC 400 SH
- Pacer Advisors, Inc. 231 SH
- Versant Capital Management, Inc 50 SH
- SJS Investment Consulting Inc. 18 SH
- Integrated Wealth Concepts LLC 7 SH
- Larson Financial Group LLC 1 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 1.7 | 945,216 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001897612-26-000762 Dispute this row |
| Forbion Growth Opportunities Fund III Cooperatief U.A. Voting Common Stock, par value $0.0001 per share | 8.4 | 4,428,328 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-462143 Dispute this row |
| Forbion Growth III Management B.V. Voting Common Stock, par value $0.0001 per share | 8.4 | 4,428,328 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-462143 Dispute this row |
| Catalyst4, Inc. Common Stock, $0.0001 par value per share | 49.9 | 27,536,011.00 | 08/14/2026 Filed 2026-08-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0001104659-26-098444 Dispute this row |
| Robert Brown Common Stock, $0.0001 par value per share | 49.9 | 27,536,011.00 | 08/14/2026 Filed 2026-08-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0001104659-26-098444 Dispute this row |
| Ekemini Riley Common Stock, $0.0001 par value per share | 49.9 | 27,536,011.00 | 08/14/2026 Filed 2026-08-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0001104659-26-098444 Dispute this row |
| Mark Vorsatz Common Stock, $0.0001 par value per share | 49.9 | 27,536,011.00 | 08/14/2026 Filed 2026-08-18 | SCHEDULE 13D/AAmendment 2 | Open filing 0001104659-26-098444 Dispute this row |
| Nan Fung Group Holdings Limited Common Stock, par value $0.0001 per share | 5.5 | 2,915,874 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| NF Investment Holdings Limited Common Stock, par value $0.0001 per share | 5.5 | 2,911,774 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Nan Fung Life Sciences Holdings Limited Common Stock, par value $0.0001 per share | 2.4 | 1,283,052 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| NFLS Platform Holdings Limited Common Stock, par value $0.0001 per share | 1.3 | 671,606 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Pivotal Life Sciences Holdings Limited Common Stock, par value $0.0001 per share | 1.2 | 611,446 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Pivotal Partners Ltd Common Stock, par value $0.0001 per share | 1.2 | 611,446 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Pivotal bioVenture Partners Fund II G.P. Ltd Common Stock, par value $0.0001 per share | 1.2 | 611,446 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Pivotal bioVenture Partners Fund II, L.P. Common Stock, par value $0.0001 per share | 1.2 | 611,446 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| NFLS Beta Limited Common Stock, par value $0.0001 per share | 1.3 | 671,606 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Permwell Management Limited Common Stock, par value $0.0001 per share | 3.1 | 1,628,722 | 08/13/2026 Filed 2026-08-20 | SCHEDULE 13G | Open filing 0001012975-26-000807 Dispute this row |
| Catalyst4, Inc. Common Stock, $0.0001 par value per share | 47.9 | 20,906,689.00 | 07/30/2026 Filed 2026-08-03 | SCHEDULE 13D/AAmendment 1 | Open filing 0001104659-26-089960 Dispute this row |
| Robert Brown Common Stock, $0.0001 par value per share | 47.9 | 20,906,689.00 | 07/30/2026 Filed 2026-08-03 | SCHEDULE 13D/AAmendment 1 | Open filing 0001104659-26-089960 Dispute this row |
| Ekemini Riley Common Stock, $0.0001 par value per share | 47.9 | 20,906,689.00 | 07/30/2026 Filed 2026-08-03 | SCHEDULE 13D/AAmendment 1 | Open filing 0001104659-26-089960 Dispute this row |
| Mark Vorsatz Common Stock, $0.0001 par value per share | 47.9 | 20,906,689.00 | 07/30/2026 Filed 2026-08-03 | SCHEDULE 13D/AAmendment 1 | Open filing 0001104659-26-089960 Dispute this row |
| Novo Holdings A/S Voting Common Stock, par value $0.0001 per share | 4.9 | 2,086,622.00 | 07/30/2026 Filed 2026-07-31 | SCHEDULE 13D/AAmendment 1 | Open filing 0001388325-26-000034 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 7.4 | 3,137,558 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0001897612-26-000505 Dispute this row |
| Forbion Growth Opportunities Fund III Cooperatief U.A. Voting Common Stock, par value $0.0001 per share | 7.1 | 3,226,400 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G | Open filing 0001193125-26-053187 Dispute this row |
| Forbion Growth III Management B.V. Voting Common Stock, par value $0.0001 per share | 7.1 | 3,226,400 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G | Open filing 0001193125-26-053187 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 6.2 | 2,799,180 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G | Open filing 0001897612-26-000296 Dispute this row |
| Catalyst4, Inc. Common Stock, $0.0001 par value per share | 45.1 | 19,697,464.00 | 10/28/2025 Filed 2025-11-20 | SCHEDULE 13D | Open filing 0001104659-25-114697 Dispute this row |
| Robert Brown Common Stock, $0.0001 par value per share | 45.1 | 19,697,464.00 | 10/28/2025 Filed 2025-11-20 | SCHEDULE 13D | Open filing 0001104659-25-114697 Dispute this row |
| Ekemini Riley Common Stock, $0.0001 par value per share | 45.1 | 19,697,464.00 | 10/28/2025 Filed 2025-11-20 | SCHEDULE 13D | Open filing 0001104659-25-114697 Dispute this row |
| Mark Vorsatz Common Stock, $0.0001 par value per share | 45.1 | 19,697,464.00 | 10/28/2025 Filed 2025-11-20 | SCHEDULE 13D | Open filing 0001104659-25-114697 Dispute this row |
| Novo Holdings A/S Voting Common Stock, par value $0.0001 per share | 8.4 | 3,686,622.00 | 10/28/2025 Filed 2025-11-04 | SCHEDULE 13D | Open filing 0001388325-25-000021 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,694,798 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 111,180 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.